P. Sleph

发表

Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1.

L. Ye, Yi-lin Li, K. Mellström, 2003, Journal of medicinal chemistry.

Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils.

K. Behnia, Rongan Zhang, P. Sleph, 2016, Cell Metabolism.

Pharmacological Characterization of a Novel Liver X Receptor Agonist with Partial LXRα Activity and a Favorable Window in Nonhuman Primates

P. Sleph, T. Kirchgessner, Richard J Martin, 2015, The Journal of Pharmacology and Experimental Therapeutics.

Microsoft Word-5751309-file00.docx

P. Sleph, T. Kirchgessner, G. Cantor, 2014 .

Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311).

David S. Taylor, Hong Shen, M. Poss, 2015, Journal of medicinal chemistry.

Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold.

L. Hamann, A. Fura, R. Seethala, 2006, Journal of medicinal chemistry.

Discovery of hydroxyl 1,2-diphenylethanamine analogs as potent cholesterol ester transfer protein inhibitors.

David S. Taylor, P. Sleph, M. Salvati, 2016, Bioorganic & medicinal chemistry letters.

Triazolopyrimidines identified as reversible myeloperoxidase inhibitors.

P. Sleph, L. Abell, D. Gordon, 2017 .

Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.

G. Grover, P. Sleph, M. Conder, 1989, The Journal of pharmacology and experimental therapeutics.

Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity.

G. Grover, P. Sleph, D. Green, 2004, American journal of physiology. Heart and circulatory physiology.

Preconditioning in rat hearts is independent of mitochondrial F1F0ATPase inhibition.

G. Grover, P. Sleph, D. Green, 1998, American journal of physiology. Heart and circulatory physiology.

Inhibition of nitric oxide synthesis does not affect ischemic preconditioning in isolated perfused rat hearts.

G. Grover, P. Sleph, A. J. Baird, 1995, The American journal of physiology.

PK/PD Disconnect Observed with a Reversible Endothelial Lipase Inhibitor.

David S. Taylor, P. Sleph, L. Abell, 2018, ACS medicinal chemistry letters.

Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.

Weiqi Wang, A. Doweyko, W. Humphreys, 2005, Journal of medicinal chemistry.

Discovery of tertiary aminoacids as dual PPARα/γ agonists-I

Wei Wang, Wei Sun, Zhengping Ma, 2007 .

A comparison between the effects of BMS-180448, a novel K+ channel opener, and cromakalim in rat and dog.

G. Grover, P. Sleph, N. Lodge, 1995, European journal of pharmacology.

Potent Triazolopyridine Myeloperoxidase Inhibitors.

P. Sleph, S. Jusuf, L. Abell, 2018, ACS medicinal chemistry letters.

Effect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia.

G. Grover, P. Sleph, J. Sewter, 1994, Cardiovascular research.

Nicorandil Improves postischemic Contractile function Independently of Direct Mycardial.Effects

G. Grover, P. Sleph, C. Parham, 1990, Journal of cardiovascular pharmacology.

Protective Effect of KATP Openers in Ischemic Rat Hearts Treated with a Potassium Cardioplegic Solution

G. Grover, P. Sleph, 1995, Journal of cardiovascular pharmacology.

Lack of a pharmacologic interaction between ATP-sensitive potassium channels and adenosine A1 receptors in ischemic rat hearts.

G. Grover, P. Sleph, A. J. Baird, 1996, Cardiovascular research.

Reduction of Skeletal Muscle Atrophy by a Proteasome Inhibitor in a Rat Model of Denervation

G. Grover, P. Sleph, B. Beehler, 2006, Experimental biology and medicine.

The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs

G. Grover, P. Sleph, C. Parham, 1990, Cardiovascular Drugs and Therapy.

Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate.

G. Grover, P. Sleph, M. Conder, 1991, Circulation research.

The ATP-sensitive potassium channel blocker glibenclamide (glyburide) does not abolish preconditioning in isolated ischemic rat hearts.

G. Grover, P. Sleph, C. Sargent, 1993, The Journal of pharmacology and experimental therapeutics.

Endogenous catecholamines are not necessary for ischaemic preconditioning in the isolated perfused rat heart.

G. Grover, P. Sleph, H. Murray, 1995, Cardiovascular research.

Adenosine A1 receptor blockade does not abolish the cardioprotective effects of the adenosine triphosphate-sensitive potassium channel opener bimakalim.

G. Grover, P. Sleph, G. Gross, 1997, The Journal of pharmacology and experimental therapeutics.

Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.

G. Grover, P. Sleph, D. W. Cushman, 1991, The Journal of pharmacology and experimental therapeutics.

In vitro effects of capsaicin: antiarrhythmic and antiischemic activity.

G. Grover, P. Sleph, J. Sewter, 1995, European journal of pharmacology.

Reduction of ischemic damage in isolated rat hearts by the potassium channel opener, RP 52891.

G. Grover, P. Sleph, S. Dzwonczyk, 1990, European journal of pharmacology.

Discovery of a Lead Triphenylethanamine Cholesterol Ester Transfer Protein (CETP) Inhibitor.

David S. Taylor, P. Sleph, M. Salvati, 2019, ACS medicinal chemistry letters.

Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.

G. Grover, P. Sleph, R. Darbenzio, 1995, Cardiovascular research.

(D)-2-tert-Butoxycarbonylamino-5,5-difluoro-5-phenyl-pentanoic acid: synthesis and incorporation into the growth hormone secretagogues.

W. Humphreys, R. Seethala, P. Sleph, 2008, Bioorganic & medicinal chemistry letters.

Myosin light-chain phosphorylation and vascular resistance in canine anterior tibial arteries in situ

S. Moreland, G. Grover, P. Sleph, 1990, Pflügers Archiv.

Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel.

M. Smith, G. Grover, P. Sleph, 1993, The Journal of pharmacology and experimental therapeutics.

Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.

David S. Nirschl, David S. Taylor, David S Nirschl, 2014, Bioorganic & medicinal chemistry letters.

N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation.

K. Kish, L. Hamann, A. Fura, 2009, Journal of medicinal chemistry.

Triazolopyrimidines identified as reversible myeloperoxidase inhibitors.

P. Sleph, L. Abell, D. Gordon, 2017, MedChemComm.

Preconditioning in rat hearts is independent of mitochondrial F1F0 ATPase inhibition.

G. Grover, P. Sleph, D. Green, 1998, The American journal of physiology.

Pharmacologic Profile of Cromakalim in the Treatment of Myocardial Ischemia in Isolated Rat Hearts and Anesthetized Dogs

G. Grover, P. Sleph, S. Dzwonczyk, 1990, Journal of cardiovascular pharmacology.

Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.

G. Grover, P. Sleph, J. Mccullough, 1993, The Journal of pharmacology and experimental therapeutics.

The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism.

G. Grover, P. Sleph, R. Darbenzio, 1994, The Journal of pharmacology and experimental therapeutics.

Tetrazole based amides as growth hormone secretagogues.

R. Seethala, G. Grover, P. Sleph, 2008, Bioorganic & medicinal chemistry letters.

Tetrahydroisoquinoline 1-carboxamides as growth hormone secretagogues.

R. Stoffel, K. Dickinson, R. Seethala, 2005, Bioorganic & medicinal chemistry letters.

Pyruvate increases threshold for preconditioning in globally ischemic rat hearts.

G. Grover, P. Sleph, C. Sargent, 1994, The American journal of physiology.

Cardioselective anti-ischemic ATP-sensitive potassium channel openers.

S. Moreland, G. Grover, P. Sleph, 1993, Journal of medicinal chemistry.

Pharmacologic Profile of the Dihydropyrimidine Calcium Channel Blockers SQ 32,547 and SQ 32,946

S. Moreland, G. Grover, P. Sleph, 1995 .

Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) inhibitors.

David S. Nirschl, David S. Taylor, David S Nirschl, 2012, Journal of medicinal chemistry.

Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats.

Stanley R Krystek, Jacek Ostrowski, K. Kish, 2007, Endocrinology.

Cardioselective antiischemic ATP-sensitive potassium channel openers. 2. Structure-activity studies on benzopyranylcyanoguanidines: modification of the benzopyran ring.

G. Grover, P. Sleph, K. Atwal, 1995, Journal of medicinal chemistry.

Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity.

W. Humphreys, G. Grover, P. Sleph, 1997, Journal of medicinal chemistry.

Pharmacologic profile of the dihydropyrimidine calcium channel blockers SQ 32,547 and SQ 32,926 [correction of SQ 32,946].

S. Moreland, G. Grover, P. Sleph, 1995, Journal of cardiovascular pharmacology.

Design and synthesis of tetrazole-based growth hormone secretagogue: the SAR studies of the O-benzyl serine side chain.

W. Humphreys, K. Dickinson, R. Seethala, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl)carbamic acid 2-{5-[1-(2-amino-2-methylpropionylamino)-2- benzyloxyethyl]tetrazol-1-yl}ethyl ester (BMS-317180).

W. Humphreys, K. Dickinson, R. Seethala, 2007, Journal of medicinal chemistry.

Cardioselective antiischemic ATP-sensitive potassium channel openers. 4. Structure-activity studies on benzopyranylcyanoguanidines: replacement of the benzopyran portion.

G. Grover, P. Sleph, C. Ding, 1996, Journal of medicinal chemistry.

Binding of ATP-sensitive potassium channel (KATP) openers to cardiac membranes: correlation of binding affinities with cardioprotective and smooth muscle relaxing potencies.

K. Dickinson, G. Grover, P. Sleph, 1998, Journal of medicinal chemistry.

Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability

Johan Malm, Liu Ye, Mark A. Smith, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Role of Myocardial ATP‐Sensitive Potassium Channels in Mediating Preconditioning in the Dog Heart and Their Possible Interaction With Adenosine A1‐Receptors

G. Grover, P. Sleph, S. Dzwonczyk, 1992, Circulation.

Effect of thromboxane receptor blockade on oxygen supply/consumption variables during reperfusion in the anesthetized dog.

H. Weiss, G. Grover, P. Sleph, 1990, The Journal of pharmacology and experimental therapeutics.

The Role of Thromboxane A2 in Reperfusion Injury

G. Grover, P. Sleph, C. Parham, 1988, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Discovery of Highly Potent Liver X Receptor β Agonists

A. D. Rodrigues, P. Sleph, T. Kirchgessner, 2016, ACS medicinal chemistry letters.

Effect of diltiazem on infarct size, reperfusion flow and flow reserve: the effect of timing of treatment.

G. Grover, P. Sleph, C. Parham, 1988, The Journal of pharmacology and experimental therapeutics.

Glyburide-reversible cardioprotective effects of BMS-180448: functional and energetic considerations.

G. Grover, P. Sleph, H. Malone, 1997, Journal of cardiovascular pharmacology.

Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators.

L. Hamann, R. Seethala, G. Grover, 2007, Bioorganic & medicinal chemistry letters.

Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides.

J. Newburger, G. Grover, P. Sleph, 1991, The Journal of pharmacology and experimental therapeutics.

Ruthenium Red Improves Postischemic Contractile Function in Isolated Rat Hearts

G. Grover, P. Sleph, S. Dzwonczyk, 1990, Journal of cardiovascular pharmacology.

Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine.

J. Baxter, G. Grover, P. Sleph, 2004, Endocrinology.

Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications.

Haixia Wang, Stanley R Krystek, Jacek Ostrowski, 2007, Journal of medicinal chemistry.

Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts.

N. Trippodo, G. Grover, P. Sleph, 1992, The Journal of pharmacology and experimental therapeutics.

Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues.

W. Humphreys, K. Dickinson, R. Seethala, 2008, Bioorganic & medicinal chemistry letters.

Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.

G. Grover, P. Sleph, N. Lodge, 2001, The Journal of pharmacology and experimental therapeutics.

Effect of Calmodulin and Protein Kinase C Inhibitors on Globally Ischemic Rat Hearts

G. Grover, P. Sleph, C. Sargent, 1992, Journal of cardiovascular pharmacology.

Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils.

Rongan Zhang, P. Sleph, T. Kirchgessner, 2016, Cell metabolism.